Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US

Drug, Healthcare and Patient Safety

Volumn 3, Issue 1, 2011, Pages 47-52

  Schumock, Glen T ^a   Gibbons, Robert D ^b   Lee, Todd A ^a,c,d   Joo, Min J ^d   Valuck, Robert J ^e   Stayner, Leslie T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HINES VA HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug safety; Leukotriene modifying agents; Montelukast; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; LEUKOTRIENE RECEPTOR AFFECTING AGENT; MONTELUKAST; ZAFIRLUKAST; ZILEUTON;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; GENDER; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRESCRIPTION; SUICIDE; UNITED STATES;

EID: 84855260938     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s23665     Document Type: Article

References (29)

1. US Food and Drug Administration. Early communication about an ongoing safety review of montelukast (Singulair), 2009. Postmarket drug safety information for patients and providers. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationfor patientsandproviders/drugsafetyinformationforhealthcareprofessionals/ucm070618.htm. Accessed June 24, 2011.
2. US Food and Drug Administration. Updated information on leukotriene inhibitors: Montelukast (marketed as Singulair), zafrlukast (marketed as Accolate), and zileuton (marketed as Zyfo and Zyfo CR), 2009. Post-market drug safety information for patients and providers. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforhealthcareprofessionals/ucm165489.htm Accessed June 24,2011
3. US Food and Drug Administration. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair), 2009. Postmarket drug safety information for patients and providers. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforhea lthcareprofessionals/ucm079523.htm. Accessed June 24, 2011.
4. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of mon-telukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568-579.
5. Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):691-696.
6. Philip G, Hustad CM, Malice M P, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):699-706.
7. [No authors listed]. Joint statement on FDA investigation of Singulair from the ACAAI and AAAAI. Eur Ann Allergy Clin Immunol. 2008; 40(2):64.
8. Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: What is the evidence? Drug Saf. 2011;34(7):533-544.
9. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165-172.
10. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;163(11):1898-1904.
11. National Center for Health Statistics. Compressed Mortality File,1999- 2006. Hyattsville, MD: National Center for Health Statistics; 2009.
12. Goodwin RD, Olfson M, Shea S, et al. Asthma and mental disorders in primary care. Gen Hosp Psychiatry. 2003;25(6):479-483.
13. Goodwin RD, Marusic A. Asthma and suicidal ideation among youth in the community. Crisis. 2004;25(3):99-102.
14. Goodwin RD, Eaton W W. Asthma, suicidal ideation, and suicide attempts: Findings from the Baltimore epidemiologic catchment area follow-up. Am J Public Health. 2005;95(4):717-722.
15. Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med. 2000;160(10):1522-1526.
16. Harwood DM, Hawton K, Hope T, Harriss L, Jacoby R. Life problems and physical illness as risk factors for suicide in older people: A descriptive and case-control study. Psychol Med. 2006;36(9):1265-1274.
17. Timonen M, Viilo K, Hakko H, et al. Is seasonality of suicides stronger in victims with hospital-treated atopic disorders? Psychiatry Res. 2004;126(2):167-175.
18. Massing W, Angermeyer MC. The monthly and weekly distribution of suicide. Soc Sci Med. 1985;21(4):433-441.
19. Chew KS, McCleary R. The spring peak in suicides: A cross-national analysis. Soc Sci Med. 1995;40(2):223-230.
20. Postolache TT, Stiller J W, Herrell R, et al. Tree pollen peaks are associated with increased nonviolent suicide in women. Mol Psychiatry. 2005;10(3):232-235.
21. Postolache TT, Komarow H, Tonelli LH. Allergy: A risk factor for suicide? Curr Treat Options Neurol. 2008;10(5):363-376.
22. Goodwin RD, Castro M, Kovacs M. Major depression and allergy: Does neuroticism explain the relationship? Psychosom Med. 2006;68(1):94-98.
23. Timonen M, Jokelainen J, Herva A, Zitting P, Meyer-Rochow VB, Rasanen P. Presence of atopy in frst-degree relatives as a predictor of a female proband's depression: Results from the northern Finland 1966 birth cohort. J Allergy Clin Immunol. 2003;111(6):1249-1254.
24. Timonen M, Jokelainen J, Hakko H, et al. Atopy and depression: Results from the Northern Finland 1966 birth cohort study. Mol Psychiatry. 2003;8(8):738-744.
25. Timonen M, Jokelainen J, Silvennoinen-Kassinen S, et al. Association between skin test diagnosed atopy and professionally diagnosed depression: A Northern Finland 1966 birth cohort study. Biol Psychiatry. 2002; 52(4):349-355.
26. Rosenberg H. Improving cause-of-death statistics. Am J Public Health. 1989;79(5):563-564.
27. Moyer LA, Boyle CA, Pollock DA. Validity of death certifcates for injury-related causes of death. Am J Epidemiol. 1989;130(5):1024-1032.
28. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
29. Lau HS, De Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997; 50(5):619-625.